Management of hepatitis C in patients with chronic kidney disease

World Journal of Gastroenterology

Volumn 21, Issue 2, 2015, Pages 408-422

  Carvalho Filho, Roberto J ^a   Feldner, Ana Cristina Ca ^a   Silva, Antonio Eduardo B ^a   Ferraz, Maria Lucia G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic kidney disease; Conservative management; Diagnosis; End stage renal disease; Hemodialysis; Hepatitis C virus; Kidney transplantation; Therapy

Indexed keywords

ANTIVIRUS AGENT;

ACUTE HEPATITIS; ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS C; HOSPITAL INFECTION; HUMAN; KIDNEY TRANSPLANTATION; REVIEW; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CROSS INFECTION; DRUG COMBINATION; HEPATITIS C, CHRONIC; MORTALITY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920964325     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i2.408     Document Type: Review

References (190)

1. Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol 2010; 6: 395-403 [PMID: 20386560 DOI: 10.1038/nrneph.2010.37]
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
3. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-357 [PMID: 23798026 DOI: 10.7326/0003-4819-159-5-201309030-00672]
4. Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, Miyakawa Y, Yoshizawa H. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol 2005; 76: 498-502 [PMID: 15977246]
5. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE; PHV Study Group. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433 [PMID: 12171969]
6. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 1322-1326 [PMID: 7508005]
7. Huang CS, Ho MS, Yang CS, Lee CL, Tan CA. Hepatitis C markers in hemodialysis patients. J Clin Microbiol 1993; 31: 1764-1769 [PMID: 7688754]
8. Su Y, Norris JL, Zang C, Peng Z, Wang N. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013; 17: 532-541 [PMID: 23072424 DOI: 10.1111/j.1542-4758.2012.00761. x]
9. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999 [PMID: 9083262]
10. Rao AK, Luckman E, Wise ME, MacCannell T, Blythe D, Lin Y, Xia G, Drobeniuc J, Noble-Wang J, Arduino MJ, Thompson ND, Patel PR, Wilson LE. Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies. Nephrol Nurs J 2013; 40: 101-10, 164; quiz 111 [PMID: 23785746]
11. Mbaeyi C, Thompson ND. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial 2013; 26: 439-446 [PMID: 23859188 DOI: 10.1111/ sdi.12097]
12. Arenas MD, Snchez-Pay J, Muoz C, Egea JJ, Martn F, Gil MT, Sarró F. [Nosocomial transmission of the hepatitis C virus in hemodialysis: monitors, personnel, or both?]. Nefrologia 2001; 21: 476-484 [PMID: 11795017]
13. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial 2010; 23: 510-515 [PMID: 21039876 DOI: 10.1111/j.1525-139X.2010.00770.x]
14. Lanini S, Abbate I, Puro V, Soscia F, Albertoni F, Battisti W, Ruta A, Capobianchi MR, Ippolito G. Molecular epidemiology of a hepatitis C virus epidemic in a haemodialysis unit: outbreak investigation and infection outcome. BMC Infect Dis 2010; 10: 257 [PMID: 20799943 DOI: 10.1186/1471-2 334-10-257]
15. Izopet J, Sandres-Saun K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76 [PMID: 16032714]
16. Lemos LB, Perez RM, Matos CA, Silva IS, Silva AE, Ferraz ML. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. J Clin Gastroenterol 2008; 42: 208-211 [PMID: 18209594 DOI: 10.1097/MCG.0b013e31802dc57f]
17. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-465 [PMID: 7777113]
18. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y. Hypoaminotransferasemia in patients undergoing long-term hemo-dialysis: clinical and biochemical appraisal. Gastroentero-logy 1995; 109: 1295-1300 [PMID: 7557098]
19. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998; 13: 62-67 [PMID: 9737574]
20. Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, Etoh Y, Shigematsu M, Kashiwagi S. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-1600 [PMID: 11374705]
21. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002; 58: 143-150 [PMID: 12227687]
22. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66: 122-129 [PMID: 7514324]
23. Carithers RL, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000; 20: 159-171 [PMID: 10946421]
24. Moreira R, Pinho JR, Fares J, Oba IT, Cardoso MR, Saraceni CP, Granato C. Prospective study of hepatitis C virus infection in hemodialysis patients by monthly analysis of HCV RNA and antibodies. Can J Microbiol 2003; 49: 503-507 [PMID: 14608385]
25. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169-176, x [PMID: 20123448 DOI: 10.1016/j.cld.2009.11.007]
26. Sleymanlar I, Sezer T, Işitan F, Yakupoglu G, Sleymanlar G. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron 1998; 79: 353-354 [PMID: 9678442]
27. Grsoy M, Gr G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-77 [PMID: 11155154]
28. Urbnek P, Tesar V, Prochzkov-Francisci E, Lachmanov J, Marecek Z, Svobodnk A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferonalpha. Treatment of hepatitis C. Blood Purif 2004; 22: 344-350 [PMID: 15258445]
29. Al-Harbi AS, Malik GH, Subaity Y, Mansy H, Abutaleb N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl 2005; 16: 293-297 [PMID: 17642795]
30. Rocha CM, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, Silva AE, Ferraz ML. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol 2007; 19: 119-123 [PMID: 17272996]
31. Ferreira Ade S, Perez Rde M, Ferraz ML, Lewis-Ximenez LL, Pereira JL, de Almeida PR, de Mattos AA; Acute Hepatitis C Study Group of The Brazilian Society of Hepatology. Acute hepatitis C in Brazil: results of a national survey. J Med Virol 2011; 83: 1738-1743 [PMID: 21837789 DOI: 10.1002/jmv.22175]
32. Engel M, Malta FM, Gomes MM, Mello IM, Pinho JR, Ono-Nita SK, Carrilho FJ. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 2007; 7: 50 [PMID: 17408470]
33. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010; 51: 541-549 [PMID: 20645865 DOI: 10.1086/655682]
34. Fabrizi F, Dixit V, Messa P, Martin P. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat 2012; 19: 784-791 [PMID: 23043385 DOI: 10.1111/ j.1365-2893.2012.01607.x]
35. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatology 2014; 59: 2101-2109 [PMID: 24442928 DOI: 10.1002/hep.26991]
36. Althaf MM, Abdelsalam MS, Rashwan M, Nadri Q. Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney? BMJ Case Rep 2014; 2014: [PMID: 24907214 DOI: 10.1136/bcr-2014-203643]
37. Rogachev B, Vorobiov M, Shnaider A, Hausmann M, Zlotnik M, Basok A. Acute viral hepatitis (C-genotype 6a and B) acquired during kidney transplantation by two patients and review of the literature. Clin Nephrol 2009; 72: 482-487 [PMID: 19954726]
38. Siddiqui AR, Abbas Z, Luck NH, Hassan SM, Aziz T, Mubarak M, Naqvi SA, Rizvi SA. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc 2012; 44: 721-724 [PMID: 22483477 DOI: 10.1016/j.transproceed.2011.12.019]
39. Delladetsima I, Psichogiou M, Sypsa V, Psimenou E, Kostakis A, Hatzakis A, Boletis JN. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis 2006; 47: 309-316 [PMID: 16431260]
40. Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994; 9: 780-784 [PMID: 7526275]
41. Ilçöl B, Ozener C, Avşar M, Ilçol Y, Lawrence R, Ozer A, Cirakoʇlu B, Akoʇlu E. Hepatitis C infection in patients with chronic renal failure receiving conservative therapy. Nephrol Dial Transplant 1997; 12: 626 [PMID: 9075165]
42. López-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolom J, Sanz P, Selgas R, Carreo V. Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001; 63: 103-107 [PMID: 11170045]
43. Lemos LB, Perez RM, Lemos MM, Lanzoni VP, Draibe SA, Silva IS, Silva AE, Ferraz ML. Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients? Am J Nephrol 2007; 27: 191-196 [PMID: 17356254]
44. Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE, Ferraz ML. Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients. Nephron Clin Pract 2008; 108: c135-c140 [PMID: 18230916 DOI: 10.1159/000114452]
45. Halfon P, Khiri H, Feryn JM, Sayada C, Chanas M, Ouzan D. Prospective virological follow-up of hepatitis C infection in a haemodialysis unit. J Viral Hepat 1998; 5: 115-121 [PMID: 9572036]
46. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000; 35: 122-129 [PMID: 10620553]
47. Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 2000; 95: 490-496 [PMID: 10685756]
48. Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002; 35: 89-92 [PMID: 12080234]
49. Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F, Vernic C, Cioca D. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? Immunopharmacol Immunotoxicol 2011; 33: 744-750 [PMID: 21320001 DOI: 10.31 09/08923973.2010.551129]
50. Bruchfeld A, Lindahl K, Schvarcz R, Sthle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708 [PMID: 12451285]
51. Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, Roberts RB. Ribavirin disposition in highrisk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546-555 [PMID: 3568539]
52. Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2: 337-339 [PMID: 15067629]
53. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004 [PMID: 10733558]
54. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-634 [PMID: 9774125]
55. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703 [PMID: 17875004]
56. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, Levy MT. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-1171 [PMID: 20861806 DOI: 10.1097/ TP.0b013e3181f92548]
57. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012; 19: 601-607 [PMID: 22863263 DOI: 10.1111/ j.1365-2893.2012.01633.x]
58. Schiavon LL, Schiavon JL, Filho RJ, Sampaio JP, Lanzoni VP, Silva AE, Ferraz ML. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 307-314 [PMID: 17634962]
59. Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol 2013; 37: 340-346 [PMID: 23933193 DOI: 10.1016/j.clinre.2013.03.005]
60. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 2004; 10: 2209-2212 [PMID: 15259067]
61. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38: 1009-1015 [PMID: 11684554]
62. Saun K, Kamar N, Midoug M, Weclawiak H, Dubois M, Izopet J, Rostaing L. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2011; 26: 2309-2316 [PMID: 21097646 DOI: 10.1093/ndt/gfq696]
63. Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B, Frei U, Berg T. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. J Hepatol 2014; 60: 928-933 [PMID: 24447875 DOI: 10.1016/j.jhep.2014.01.012]
64. Ishida H, Tanabe K, Tokumoto T, Shimizu T, Shimmura H, Yoshioka T, Toma H. Hepatitis C virus decreases in patients with maintenance hemofiltration therapy. Artif Organs 2004; 28: 316-318 [PMID: 15046633]
65. Dussol B, de Lamballerie X, Brunet P, Roubicek C, Chicheportiche C, Cantaloube JF, Biagini P, de Micco P, Ber-land Y. Is hepatitis C virus-RNA detection by nested poly-merase chain reaction clinically relevant in hemodialysis patients? Clin Nephrol 1996; 45: 257-260 [PMID: 8861802]
66. Galn F, Prez-Gracia MT, Lozano A, Benavides B, Fernandez-Ruz E, Rodrguez-Iglesias MA. A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1211-1214 [PMID: 9623556]
67. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol 2003; 16: 467-475 [PMID: 14696748]
68. Dzekova-Vidimliski P, Asani A, Selim G, Gelev S, Polenakovic M, Sikole A. Patterns of viraemia in haemodialysis patients with hepatitis C. Prilozi 2008; 29: 201-211 [PMID: 19259047]
69. Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI. Effect of heparin on polymerase chain reaction. Lancet 1994; 343: 1509-1510 [PMID: 7911214]
70. Okuda K, Hayashi H, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by haemodialysis. Lancet 1996; 347: 909-910 [PMID: 8622434]
71. Rampino T, Libetta C, Mazzone A, Gregorini M, Soccio G, Ranghino A, Maggio M, Guallini P, Girola S, Dal Canton A. Hepatocyte growth factor protects the liver against hepatitis C virus in patients on regular hemodialysis. J Chemother 1998; 10: 164-166 [PMID: 9603647]
72. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Salvadori M, Como G, Ponticelli C, Graziani G. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis 2003; 42: 143-150 [PMID: 12830466]
73. Fabrizi F, Messa P, Martin P. Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight. Int J Artif Organs 2009; 32: 1-11 [PMID: 19241358]
74. Khan N, Aswad S, Shidban H, Aghajani M, Mendez R, Mendez R, Comanor L. Improved detection of HCV Infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. J Clin Virol 2004; 30: 175-182 [PMID: 15125874]
75. Rao V, Fabrizi F, Pennell P, Schiff E, de Medina M, Lane JR, Martin P, Ivor L. Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population. Ren Fail 2010; 32: 721-726 [PMID: 20540641 DOI: 10.3109/0886022X.2010.486499]
76. Bastos DO, Perez RM, Silva IS, Lemos LB, Simonetti JP, Medina-Pestana JO, Silva AE, Ferraz ML. Transcriptionmediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C. J Med Virol 2012; 84: 596-600 [PMID: 22337298 DOI: 10.1002/jmv.23216]
77. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142: 1303-1313.e1 [PMID: 22537437 DOI: 10.1053/j.gastro.2012.02.027]
78. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500 [PMID: 11172192]
79. Sabovic M, Salobir B, Preloznik Zupan I, Bratina P, Bojec V, Buturovic Ponikvar J. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2005; 34: 274-278 [PMID: 16772739]
80. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, Jensik S, Jensen DM. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-195 [PMID: 12172367]
81. Ahmad A, Hasan F, Abdeen S, Sheikh M, Kodaj J, Nampoory MR, Johny KV, Asker H, Siddique I, Thalib L, Al-Nakib B. Transjugular liver biopsy in patients with endstage renal disease. J Vasc Interv Radiol 2004; 15: 257-260 [PMID: 15028810]
82. Ozdoʇan M, Ozgr O, Boyacioʇlu S, Coşkun M, Kart H, Ozdal S, Telatar H. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996; 74: 442-443 [PMID: 8893179]
83. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T, Spengler U. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67: 138-145 [PMID: 12853725]
84. Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin Gastroenterol Hepatol 2007; 5: 1316-1320 [PMID: 17904916]
85. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005; 80: 1550-1555 [PMID: 16371924]
86. Liu CH, Liang CC, Liu CJ, Hsu SJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney Int 2010; 78: 103-109 [PMID: 20357753 DOI: 10.1038/ki.2010.74]
87. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen JH, Chen DS, Kao JH. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol 2011; 6: 1057-1065 [PMID: 21393486 DOI: 10.2215/ CJN.04320510]
88. Singh N, Neidlinger N, Djamali A, Leverson G, Voss B, Sollinger HW, Pirsch JD. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012; 26: 684-693 [PMID: 22283142 DOI: 10.1111/ j.1399-0012.2011.01583.x]
89. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyó JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360 [PMID: 12614294]
90. Guitard J, Rostaing L, Kamar N. New-onset diabetes and nephropathy after renal transplantation. Contrib Nephrol 2011; 170: 247-255 [PMID: 21659777 DOI: 10.1159/000325778]
91. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Brchot C, Pol S. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-133 [PMID: 11773476]
92. de Oliveira Uehara SN, Emori CT, da Silva Fucuta Pereira P, Perez RM, Pestana JO, Lanzoni VP, e Silva IS, Silva AE, Ferraz ML. Histological evolution of hepatitis C virus infection after renal transplantation. Clin Transplant 2012; 26: 842-848 [PMID: 22594774 DOI: 10.1111/j.1399-0012.2012.01635.x]
93. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-1461 [PMID: 15888054]
94. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-1422 [PMID: 17081162]
95. Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-1615 [PMID: 12873587]
96. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-1081 [PMID: 14653826]
97. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008; 51: 263-277 [PMID: 18215704 DOI: 10.1053/j.ajkd.2007.11.003]
98. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis-an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009; 4: 1449-1458 [PMID: 19643927 DOI: 10.2215/CJN.01850309]
99. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. J Viral Hepat 2008; 15: 600-606 [PMID: 18444984 DOI: 10.1111/j.1365-2893.2008.00990.x]
100. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010; 4: 181-194 [PMID: 20622305]
101. Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. J Med Virol 2010; 82: 768-775 [PMID: 20336712 DOI: 10.1002/jmv.21542]
102. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: metaanalysis of clinical trials. J Viral Hepat 2011; 18: e263-e269 [PMID: 21108701 DOI: 10.1111/j.1365-2893.2010.01405.x]
103. Fabrizi F, Dixit V, Messa P, Martin P. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J Viral Hepat 2014; 21: 681-689 [PMID: 25040244 DOI: 10.1111/jvh.12276]
104. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, Hung PH, Kao JH, Liu CJ, Lai MY, Chen JH, Chen PJ, Kao JH, Chen DS. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530 [PMID: 17881538]
105. Bruchfeld A, Sthle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2001; 16: 1729 [PMID: 11477195]
106. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-1834 [PMID: 15350490]
107. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-321 [PMID: 16637862]
108. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-774 [PMID: 17383045]
109. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008; 23: 721-725 [PMID: 18042614]
110. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008; 31: 295-302 [PMID: 18432584]
111. Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol 2009; 43: 477-481 [PMID: 19142165 DOI: 10.1097/MCG.0b013e318180803a]
112. Liu CH, Liang CC, Liu CJ, Tsai HB, Hung PH, Hsu SJ, Chen SI, Lin JW, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009; 58: 314-316 [PMID: 19136527 DOI: 10.1136/gut.2008.165076]
113. Alsaran K, Sabry A, Shaheen N. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience. Int Urol Nephrol 2011; 43: 865-873 [PMID: 20490669 DOI: 10.1007/s11255-010-9756-1]
114. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013; 159: 729-738 [PMID: 24297189 DOI: 10.7326 /0003-4819-159-11-201312030-00005]
115. Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Peginterferon alfa-2a with or without lowdose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut 2014 Apr 19; Epub ahead of print [PMID: 24747867 DOI: 10.1136/gutjnl-2014-307080]
116. Fucuta Pereira Pda S, Uehara SN, de Mello Perez R, Feldner AC, de Melo IC, de Souza e Silva IS, Silva AE, Ferraz ML. Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients? Int J Infect Dis 2013; 17: e50-e53 [PMID: 23041364 DOI: 10.1016/j.ijid.2012.09.001]
117. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-149 [PMID: 23149155 DOI: 10.1016/j.jcv. 2012.10.009]
118. Knapstein J, Galle PR, Zimmermann T. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. Dig Liver Dis 2014; 46: 88-89 [PMID: 24054768 DOI: 10.1016/j.dld.2013.08.133]
119. Slim J, Scangarello N, Samaha P, Dazley J. A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease. Int J STD AIDS 2014; 25: 830-832 [PMID: 24557545]
120. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Aliment Pharmacol Ther 2014; 39: 1342-1344 [PMID: 24803258 DOI: 10.1111/apt. 12748]
121. Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, OMara E, Kasserra C, Gupta S, Hughes EA. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012; 51: 619-628 [PMID: 22799589 DOI: 10.2165/11633440-000000000-00000]
122. de Kanter CT, den Hollander JG, Verweij-van Wissen CP, Burger DM. Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis. J Clin Virol 2014; 60: 431-432 [PMID: 24929751 DOI: 10.1016/j.jcv.2014.05.008]
123. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263 [PMID: 9862875]
124. Paramesh AS, Davis JY, Mallikarjun C, Zhang R, Cannon R, Shores N, Killackey MT, McGee J, Saggi BH, Slakey DP, Balart L, Buell JF. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation 2012; 94: 250-254 [PMID: 22790385 DOI: 10.1097/TP.0b013 e318255f890]
125. Campos S, Parsikia A, Zaki RF, Ortiz JA. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation 2012; 94: e65-e66 [PMID: 23222741 DOI: 10.1097/TP.0b013e318274abc1]
126. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Pron JM, Vinel JP, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-1499 [PMID: 12404224]
127. Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, Izopet J. Natural history of hepatitis C virusrelated liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-1712 [PMID: 15943629]
128. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670 [PMID: 9521201]
129. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz WH. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-136 [PMID: 11966783]
130. Ridruejo E, Daz C, Michel MD, Soler Pujol G, Martnez A, Marciano S, Mandó OG, Vilches A. Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. Ann Hepatol 2010; 9: 271-277 [PMID: 20720267]
131. Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon 2011; 11: 247-254 [PMID: 22087151]
132. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 2014; 21: 314-324 [PMID: 24716634 DOI: 10.1111/jvh.12148]
133. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805 [PMID: 7482738]
134. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-495 [PMID: 16549157]
135. Fabrizi F, Messa P, Martin P, Takkouche B. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. Int J Artif Organs 2008; 31: 675-682 [PMID: 18825640]
136. Pol S, Cavalcanti R, Carnot F, Legendre C, Driss F, Chaix ML, Thervet E, Chkoff N, Brechot C, Berthelot P, Kreis H. Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Transplantation 1996; 61: 1774-1776 [PMID: 8685959]
137. Preiksaitis JK, Cockfield SM, Fenton JM, Burton NI, Chui LW. Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation 1997; 64: 1775-1780 [PMID: 9422419]
138. Roth D, Zucker K, Cirocco R, Burke G, Ciancio G, Esquenazi V, Swanson SJ, Miller J. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-889 [PMID: 8623154]
139. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-1041 [PMID: 16143140]
140. Fernandes F, Poole DS, Hoover S, Middleton R, Andrei AC, Gerstner J, Striker R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007; 46: 1026-1033 [PMID: 17600342]
141. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288 [PMID: 14578868]
142. Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mhlbacher F, Leonardi L, Cillo U. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006; 38: 2964-2967 [PMID: 17112875]
143. Rayhill SC, Barbeito R, Katz D, Voigt M, Labrecque D, Kirby P, Miller R, Stolpen A, Wu Y, Schmidt W. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc 2006; 38: 3625-3628 [PMID: 17175350]
144. Kamar N, Selves J, Sandres-Saune K, Durand D, Izopet J, Rostaing L. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? Transplant Proc 2006; 38: 1329-1332 [PMID: 16797294]
145. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Barbosa DV, Lanzoni VP, Ferraz ML, Silva AE. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology 2008; 48: 348-349 [PMID: 18521870 DOI: 10.1002/hep.22331]
146. Manuel O, Baid-Agrawal S, Moradpour D, Pascual M. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol 2012; 176: 97-107 [PMID: 22310785 DOI: 10.1159/000332387]
147. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-934 [PMID: 11684543]
148. Giordano HM, França AV, Meirelles L, Escanhoela CA, Nishimura NF, Santos RL, Quadros KR, Mazzali M, Alves-Filho G, Soares EC. Chronic liver disease in kidney recipients with hepatitis C virus infection. Clin Transplant 2003; 17: 195-199 [PMID: 12780667]
149. Perez RM, Ferreira AS, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection? Clin Transplant 2005; 19: 622-625 [PMID: 16146553]
150. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (109): S1-99 [PMID: 18382440 DOI: 10.1038/ki.2008.81]
151. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1-155 [PMID: 19845597 DOI: 10.1111/ j.1600-6143.2009.02834.x]
152. Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, Lauwers-Cances V, Rostaing L. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transpl Int 2009; 22: 568-573 [PMID: 19196449 DOI: 10.1111/j.1432-2277.2009.00834.x]
153. Muoz R, Ramrez E, Fernandez I, Martin A, Romero M, Romero E, Dominguez-Gil B, Hernandez A, Morales E, Andres A, Castellano G, Morales JM. Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis C virus infection after renal transplantation. Transplant Proc 2009; 41: 2425-2426 [PMID: 19715940 DOI: 10.1016/j.transproceed.2009.06.103]
154. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 2075 [PMID: 8066675]
155. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-628 [PMID: 7916505]
156. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alphainduced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070 [PMID: 7709447]
157. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431 [PMID: 7770930]
158. Ozgr O, Boyacioʇlu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-2106 [PMID: 8643176]
159. Yasumura T, Nakajima H, Hamashima T, Nakai I, Yoshimura N, Ohmori Y, Oka T. Long-term outcome of recombinant INF-alpha treatment of chronic hepatitis C in kidney transplant recipients. Transplant Proc 1997; 29: 784-786 [PMID: 9123525]
160. Durlik M, Gaciong Z, Rowińska D, Rancewicz Z, Lewandowska D, Kozłowska B, Wyzgał J, Soluch L, Walewska-Zielecka B, Rowiński W, Lao M. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 Suppl 1: S135-S139 [PMID: 9664963]
161. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476 [PMID: 9734490]
162. Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, Gouya N, Nakazawa H, Hashimoto E, Fuchinoue S, Hayashi N, Toma H. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 1998; 30: 3270-3272 [PMID: 9838445]
163. Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78 [PMID: 12492714]
164. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, Neng Lai K, Mao Chan T. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878 [PMID: 14568274]
165. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894-1896 [PMID: 15223909]
166. Izopet J, Rostaing L, Ton-That H, Dubois M, Cazabat M, Charlet JP, Sayada C, Duffaut M, Durand D, Puel J. Kinetics of HCV viremia in kidney transplant recipients during and after alpha-interferon therapy. Am J Nephrol 1997; 17: 417-420 [PMID: 9382158]
167. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-683 [PMID: 17100715]
168. Pageaux GP, Hilleret MN, Garrigues V, Bismuth M, Audin-Mamlouk H, Zarski JP, Mourad G. Pegylated interferonalpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int 2009; 22: 562-567 [PMID: 19175562 DOI: 10.1111/j.1432-2277. 2008.00831.x]
169. Aljumah AA, Saeed MA, Al Flaiw AI, Al Traif IH, Al Alwan AM, Al Qurashi SH, Al Ghamdi GA, Al Hejaili FF, Al Balwi MA, Al Sayyari AA. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012; 18: 55-63 [PMID: 22228971 DOI: 10.3748/wjg.v18.i1.55]
170. Sanai FM, Mousa D, Al-Mdani A, Al-Shoail G, Al-Ashgar H, Al Meshari K, Al-Qahtani A, Saadeh M, Bzeizi KI, Aleid H. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol 2013; 58: 1096-1103 [PMID: 23428875 DOI: 10.1016/j.jhep.2013.02.004]
171. Wei F, Liu J, Liu F, Hu H, Ren H, Hu P. Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One 2014; 9: e90611 [PMID: 24699257 DOI: 10.1371/journal.pone.0090611]
172. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.10 02/hep.22759]
173. Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med 2010; 3: 1-13 [PMID: 23226039]
174. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212-223 [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21]
175. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867-876 [PMID: 10831463]
176. Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606 [PMID: 23817323 DOI: 10.1038/nrgastro.2013.106]
177. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of sideeffects. Liver Int 2013; 33 Suppl 1: 30-34 [PMID: 23286843 DOI: 10.1111/liv.12080]
178. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
179. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
180. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
181. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
182. Cacoub P, Bourlire M, Lbbe J, Dupin N, Buggisch P, Dusheiko G, Hzode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-463 [PMID: 21884670 DOI: 10.1016/j.jhep.2011.08.006]
183. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
184. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413 [PMID: 24907225
185. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426 [PMID: 24907224
186. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegin-terferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3 [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051]
187. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
188. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI: 10.1016/ S0140-6736(14)61036-9]
189. Cornpropst MT, Denning JM, Clemons D, Marbury TC, Alcorn H, Smith WB, Sale M, Fang L, Berrey MM, Symonds WT. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012; 56 (Suppl.2): S443
190. AbbVie. Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in Treatment-Nave HCV Genotype 1-Infected Adults With Chronic Kidney Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000: [cited 2014 Aug 20], NLM Identifier: NCT02207088